Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01478620
Other study ID # CanUTI2
Secondary ID 2011-000838-11
Status Completed
Phase Phase 3
First received
Last updated
Start date October 2011
Est. completion date August 2012

Study information

Verified date February 2019
Source Bionorica SE
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the study is to assess safety and impact of a non-antibiotic therapy approach with Canephron® N in the management strategy of uncomplicated lower urinary tract infections (UTIs).


Description:

250 patients total 7-day treatment period with Canephron® N (2 tablets three times a day) and a follow-up period until Day 37. A total of three visits are planned on Day 0 (screening, start of study treatment), Day 7 (end of study treatment) and Day 37 (end of study visit).

Additional visits can be performed anytime between Day 1 and Day 37 if deemed necessary by the investigator. In case the patients experience consistent or worsening of symptoms they may be offered antibiotic therapy at the discretion of the investigator at any time. In this case Canephron® N intake will be stopped.

At least 50% of the patients, i.e. 125 subjects, should have received a 7-day treatment with Canephron® N. If less subjects are available recruitment of subjects will be continued until the required number of 125 subjects is reached.

Due to withdrawal of study in Russia total study population was reduced to 125 patients.


Recruitment information / eligibility

Status Completed
Enrollment 125
Est. completion date August 2012
Est. primary completion date May 2012
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Main Inclusion Criteria:

- Female outpatients aged 18-65 years (both inclusive).

- Patients suffering of symptoms of uncomplicated lower urinary infection at screening. Patients must have a total sum score of at least six for the symptoms dysuria, frequency and urgency.

- Development of symptoms within a maximum of 6 days before screening.

- Willing to refrain from consuming prohibited concomitant medications and products.

- Non-lactating female patients, who are surgically sterile (have had a documented bilateral oophorectomy and/or hysterectomy) or postmenopausal (cessation of menses for more than 1 year), or patients of childbearing potential with a negative pregnancy test at screening willing to use effective contraception methods (intrauterine device [IUD], hormonal contraceptives) during the study.

Main Exclusion Criteria:

- Any signs evoking complicated UTI, pyelonephritis and/or concomitant vulvo-vaginitis

- Any conditions that may lead to complicated infections (that is, renal diseases, urinary tract abnormalities or past urinary surgery, urine catheterization, etc).

- Chronic infection of the urinary tract requiring an intravenous pyelogram (IVP), ultrasound or cystoscopy.

- Current signs or symptoms of severe, progressive or uncontrolled life-threatening systemic disease i.e. renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease.

- Other acute infection (except UTI) requiring antibiotic treatment.

- Patients receiving treatment for presumed or proven urinary tract infection within 4 weeks prior to study entry.

- Antibiotic, immunosuppressive or immunostimulant (incl. vaccines) therapy within 4 weeks prior to study entry.

- Patients with known history of anatomical genitourinary (GU) anomalies or GU surgery within 6 months prior to study entry.

- Patients with known clinically significant abnormalities in screening physical examination, laboratory tests or vital signs.

- Peptic ulcers and hypersensitivity and/or idiosyncrasy to centaury herb, lovage root, rosemary leaves or one of the other ingredients of the investigational medicinal product.

- Rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency, galactose intolerance or lactase deficiency.

- Patients with a history of severe drug allergy or hypersensitivity.

- Known Human Immunodeficiency Virus (HIV)-seropositivity.

Study Design


Intervention

Drug:
Canephron® N
3x 2 coated tablets/day for 7 days p.o.

Locations

Country Name City State
Ukraine Kiev Regional City Hospital Kiev

Sponsors (1)

Lead Sponsor Collaborator
Bionorica SE

Country where clinical trial is conducted

Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse Drug Reactions During 7-day Treatment of uUTI Symptoms With Canephron® N No study drug related adverse drug reactions were registered. During active treatment period (day 1 until day 7)
Secondary Incidence of Adverse Drug Reactions During the 7-day Treatment of uUTI Symptoms With Canephron® N in the Subgroup of Patients Who Take Canephron® N for at Least 7 Days During active treatment period
Secondary Proportion of Patients With no Symptoms Worse Than Mild on Day 7 (i.e. Responders) Day 7
Secondary Severity of uUTI Symptoms on Day 7 Day 7
Secondary Severity of uUTI Symptoms on Day 37 Day 37
Secondary Duration of uUTI Symptoms During active treatment and follow up period (Day 0 - Day 37)
Secondary Proportion of Patients Who Require Antibiotic Treatment Until Day 7 During active treatment period
Secondary Proportion of Patients With Early Recurrence [Days] After Clearance of uUTI Symptoms During active treatment and follow up period (Day 0 - Day 37)
Secondary Time to First Early Recurrence [Days] After Clearance of uUTI Symptoms During active treatment and follow up period (Day 0 - Day 37)
See also
  Status Clinical Trial Phase
Completed NCT03235947 - Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients Phase 4
Withdrawn NCT01881165 - Cranberry on Urinary Tract Infections Phase 4
Terminated NCT02198833 - Efficacy of Micro-Patterned Foley Catheter to Reduce Catheter-Associated Urinary Tract Infection N/A
Completed NCT01687114 - Urinary Proanthocyanidin-A2 as a Biomarker of Compliance to Intake of Cranberry Products N/A
Completed NCT02357758 - Effects of Antibiotic Prophylaxis on Recurrent UTI in Children Phase 4
Completed NCT01391793 - Corticosteroids for Children With Febrile Urinary Tract Infections Phase 3
Completed NCT01219595 - Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible Women N/A
Completed NCT00365430 - SAFE or SORRY? Patient Safety Study of the Prevention of Adverse Patient Outcomes N/A
Recruiting NCT04502095 - Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy Phase 4
Completed NCT00976963 - Single Dose Monurol for Treatment of Acute Cystitis N/A
Recruiting NCT02568800 - Prolonged Infusion Cefepime and Nosocomial Infections Phase 3
Completed NCT02785445 - Healthy.io Method Comparison & User Performance Study N/A
Completed NCT02216253 - L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract to Prevent Postoperative Urinary Tract Infection. N/A
Completed NCT01054690 - Silver Alloyed Urinary Catheters and Incidence of Catheter Acquired Urinary Tract Infections (UTI) N/A
Completed NCT00371631 - Colonizing Neurogenic Bladders With Benign Flora Phase 1
Terminated NCT03697993 - Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS) Phase 4
Terminated NCT01803919 - Efficacy Study of Antimicrobial Catheters to Avoid Urinary Infections in Spinal Cord Injured Patients N/A
Enrolling by invitation NCT01231737 - Efficacy of Two Prophylactic Schedules (Prulifloxacin Versus Phosphomycin) Phase 2
Completed NCT01763008 - A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections Phase 4
Completed NCT00528476 - Risk Factors for Recurrent Urinary Tract Infection in Children N/A